MEDtalk: The long-term benefits for patients with stage IV/recurrent NSCLC in a perspective of CheckMate 227

Best Practice Nordic | Jul 2020 | ASCO20 Virtual |

Hear Professor Martin Reck explain the long-term benefits for patients with stage IV/recurrent NSCLC in a perspective of CheckMate 227 and the key take-aways from ASCO 2020 within the area of lung cancer.